Suppression of AAV-Delivered Transgene Expression Using Artificial MicroRNAs Delivered by an Alternative AAV Serotype

HUMAN GENE THERAPY · Published 2026-08-05 · DOI 10.1177/10430342261457812

Authors (5)

Miguel de Mulder Rougvie, Mara R. Kebret, Youjun Wu, Katie M. Stiles, Ronald G. Crystal

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Rougvie, M., Kebret, M., Wu, Y., et al. (2026). Suppression of AAV-Delivered Transgene Expression Using Artificial MicroRNAs Delivered by an Alternative AAV Serotype. HUMAN GENE THERAPY. https://doi.org/10.1177/10430342261457812

Related articles

• Directed evolution of liver-detargeted AAV vectors for systemic gene delivery to skeletal muscle and heart · MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT · 2025 · Cites or is cited by this article
• Retroviral Transduction of Human CD4 + T Cells with Membrane-Attached IL-10 Generates Type 1-Like Regulatory T Cells · HUMAN GENE THERAPY · 2026 · Same journal
• Optimization of Alpha-1 Antitrypsin Expression from Adeno-Associated Virus Vectors · HUMAN GENE THERAPY · 2026 · Same journal
• Prenatal Intraportal Delivery of Polymeric Nanoparticles to Fetal Rhesus Monkeys ( Macaca mulatta ) · HUMAN GENE THERAPY · 2026 · Same journal
• High Prevalence of Preexisting Neutralizing Antibodies Against Adeno-Associated Virus Capsids in Mongolian People with Hemophilia · HUMAN GENE THERAPY · 2026 · Same journal
• Quantification of Lentiviral Vectors with Nucleic Acid Dyes · HUMAN GENE THERAPY · 2026 · Same journal
• CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences · HUMAN GENE THERAPY · 2026 · Same journal
• A Review of the Challenge of Pre-Existing Humoral Immunity in Adeno-Associated Virus Gene Therapy and Potential Solutions · HUMAN GENE THERAPY · 2026 · Same journal
• Capsid Engineering of Adeno-Associated Viruses for Targeted Gene Therapy in Kidney Diseases · HUMAN GENE THERAPY · 2026 · Same journal
• Ethical and Regulatory Considerations for Developing Gene Therapies Involving Genome Editing · HUMAN GENE THERAPY · 2026 · Same journal